Therapeutic Response

ER negative status confers therapeutic sensitivity to Fulvestrant in patients with Invasive Breast Carcinoma.

Statements

Source and description
Fulvestrant Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved fulvestrant for reimbursement as a treatment option for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-estrogen therapy in patients who are postmenopausal women.
Fulvestrant Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved fulvestrant for reimbursement as a treatment option for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer for disease progression on or after adjuvant anti-estrogen therapy in patients who are postmenopausal women.